Insmed Incorporated (NASDAQ:INSM) COO Roger Adsett Sells 1,457 Shares

Insmed Incorporated (NASDAQ:INSM) COO Roger Adsett sold 1,457 shares of Insmed stock in a transaction on Tuesday, January 14th. The shares were sold at an average price of $68.72, for a total transaction of $100,125.04. Following the completion of the transaction, the chief operating officer now owns 146,082 shares in the company, valued at approximately $10,038,755.04. This represents a 0.99 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Roger Adsett also recently made the following trade(s):

• On Friday, January 10th, Roger Adsett sold 4,902 shares of Insmed stock. The shares were sold at an average price of $63.68, for a total transaction of $312,159.36.
• On Tuesday, January 7th, Roger Adsett sold 2,444 shares of Insmed stock. The shares were sold at an average price of $65.95, for a total transaction of $161,181.80.

Insmed Stock Down 0.3 %

Shares of NASDAQ INSM opened at $72.51 on Friday. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $80.53. The company has a market capitalization of $12.97 billion, a PE ratio of -13.06 and a beta of 1.12. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The firm’s 50-day moving average is $71.18 and its two-hundred day moving average is $72.57.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The business had revenue of $93.40 million for the quarter, compared to the consensus estimate of $93.36 million. During the same quarter in the previous year, the business earned ($1.10) earnings per share. Insmed’s quarterly revenue was up 18.1% on a year-over-year basis. Equities analysts anticipate that Insmed Incorporated will post -5.44 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $90.00 target price on shares of Insmed in a report on Friday, November 1st. Truist Financial reaffirmed a “buy” rating and issued a $105.00 target price (up previously from $100.00) on shares of Insmed in a report on Friday, November 1st. JPMorgan Chase & Co. lifted their target price on shares of Insmed from $74.00 to $83.00 and gave the company an “overweight” rating in a report on Friday, November 22nd. Finally, Bank of America lifted their target price on shares of Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a report on Wednesday, October 9th. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $83.67.

Hedge Funds Weigh In On Insmed

A number of institutional investors have recently modified their holdings of INSM. Private Advisor Group LLC acquired a new position in shares of Insmed in the second quarter valued at approximately $575,000. Federated Hermes Inc. raised its position in shares of Insmed by 11,879.8% in the second quarter. Federated Hermes Inc. now owns 10,063 shares of the biopharmaceutical company’s stock valued at $674,000 after buying an additional 9,979 shares during the last quarter. Oppenheimer Asset Management Inc. acquired a new position in shares of Insmed in the second quarter valued at approximately $449,000. Envestnet Asset Management Inc. raised its position in shares of Insmed by 211.9% in the second quarter. Envestnet Asset Management Inc. now owns 175,464 shares of the biopharmaceutical company’s stock valued at $11,756,000 after buying an additional 119,214 shares during the last quarter. Finally, Dimensional Fund Advisors LP acquired a new position in shares of Insmed in the second quarter valued at approximately $810,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.